Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
26-28 August, 2025
KY/TN Water Profession...KY/TN Water Professionals
Not Confirmed
Not Confirmed
27-30 July, 2025
Chemicals AmericaChemicals America
Not Confirmed
Not Confirmed
29-31 July, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
26-28 August, 2025
KY/TN Water Profession...KY/TN Water Professionals
Industry Trade Show
Not Confirmed
27-30 July, 2025
Chemicals AmericaChemicals America
Industry Trade Show
Not Confirmed
29-31 July, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint
17 Jul 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250717210406/en/PureTech-Founded-Entity-Seaport-Therapeutics-Announces-First-Patient-Dosed-in-Phase-2b-BUOY-1-Study-of-GlyphAllo-SPT-300-in-Major-Depressive-Disorder-MDD-With-or-Without-Anxious-Distress
22 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250522099865/en/PureTech-to-Present-at-the-Jefferies-Global-Healthcare-Conference
21 May 2025
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/puretech-shows-durability-pulmonary-fibrosis-candidate-deupirfenidone
09 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250509578009/en/PureTech-Announces-Publication-of-New-Research-Highlighting-Untold-Experiences-of-People-Living-with-Idiopathic-Pulmonary-Fibrosis-IPF
01 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250501295892/en/PureTech-to-Present-Results-from-Phase-2b-ELEVATE-IPF-Trial-of-Deupirfenidone-LYT-100-at-the-American-Thoracic-Society-International-Conference
30 Apr 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250429821901/en/PureTech-Announces-Annual-Results-for-Year-Ended-December-31-2024
Details:
LYT-200 is a fully human IgG4 monoclonal antibody (mAb) targeting galectin-9. It is being advanced in hematological malignancies such as acute myeloid leukemia AML, MDS, and solid tumors.
Lead Product(s): LYT-200
Therapeutic Area: Oncology Brand Name: LYT-200
Study Phase: Phase IProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 09, 2025
PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)
Details : LYT-200 is a fully human IgG4 monoclonal antibody (mAb) targeting galectin-9. It is being advanced in hematological malignancies such as acute myeloid leukemia AML, MDS, and solid tumors.
Product Name : LYT-200
Product Type : Antibody
Upfront Cash : Inapplicable
January 09, 2025
Details:
LYT-100 (deupirfenidone) is an inhibitor of IL-6 and TNF alpha. It is being evaluated for the treatment of patients with idiopathic pulmonary fibrosis.
Lead Product(s): Deupirfenidone
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: LYT-100
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 16, 2024
Lead Product(s) : Deupirfenidone
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PureTech’s Deupirfenidone Slows IPF Lung Function Decline in ELEVATE Phase 2b Trial
Details : LYT-100 (deupirfenidone) is an inhibitor of IL-6 and TNF alpha. It is being evaluated for the treatment of patients with idiopathic pulmonary fibrosis.
Product Name : LYT-100
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 16, 2024
Details:
LYT-100 (deupirfenidone) is an inhibitor of IL-6 and TNF alpha. It is being evaluated for the treatment of patients with idiopathic pulmonary fibrosis.
Lead Product(s): Deupirfenidone
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: LYT-100
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 16, 2024
Lead Product(s) : Deupirfenidone
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PureTech Completes Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 in PF
Details : LYT-100 (deupirfenidone) is an inhibitor of IL-6 and TNF alpha. It is being evaluated for the treatment of patients with idiopathic pulmonary fibrosis.
Product Name : LYT-100
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 16, 2024
Details:
LYT-200 is a IgG4 monoclonal antibody targeting galectin-9, a potent oncogenic driver in leukemia cells. It is being advanced in hematological malignancies such as AML, MDS.
Lead Product(s): LYT-200
Therapeutic Area: Oncology Brand Name: LYT-200
Study Phase: Phase IProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 13, 2024
PureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid Leukemia
Details : LYT-200 is a IgG4 monoclonal antibody targeting galectin-9, a potent oncogenic driver in leukemia cells. It is being advanced in hematological malignancies such as AML, MDS.
Product Name : LYT-200
Product Type : Antibody
Upfront Cash : Inapplicable
March 13, 2024
Details:
LYT-300 (allopregnanolone prodrug) is a positive allosteric modulator of γ-aminobutyric-acid type A (GABAA) receptors and has been shown to regulate mood and other neurological conditions. It is be developed for anxiety and postpartum depression treatment.
Lead Product(s): Allopregnanolone
Therapeutic Area: Psychiatry/Psychology Brand Name: LYT-300
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 14, 2023
Lead Product(s) : Allopregnanolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LYT-300 (allopregnanolone prodrug) is a positive allosteric modulator of γ-aminobutyric-acid type A (GABAA) receptors and has been shown to regulate mood and other neurological conditions. It is be developed for anxiety and postpartum depression treatme...
Product Name : LYT-300
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 14, 2023
Details:
KarXT (xanomeline-trospium) is an oral, investigational M1/M4-preferring muscarinic agonist in development for the treatment of psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer’s disease.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Brand Name: KarXT
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Karuna Therapeutics
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 28, 2023
Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Karuna Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
KarXT, invented at PureTech, submitted for FDA Approval in Schizophrenia
Details : KarXT (xanomeline-trospium) is an oral, investigational M1/M4-preferring muscarinic agonist in development for the treatment of psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer’s disease.
Product Name : KarXT
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 28, 2023
Details:
LYT-300 (allopregnanolone prodrug) is a positive allosteric modulator of γ-aminobutyric-acid type A (GABAA) receptors and has been shown to regulate mood and other neurological conditions. It is be developed for anxiety and postpartum depression treatment.
Lead Product(s): Allopregnanolone
Therapeutic Area: Psychiatry/Psychology Brand Name: LYT-300
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 21, 2023
Lead Product(s) : Allopregnanolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LYT-300 (allopregnanolone prodrug) is a positive allosteric modulator of γ-aminobutyric-acid type A (GABAA) receptors and has been shown to regulate mood and other neurological conditions. It is be developed for anxiety and postpartum depression treatme...
Product Name : LYT-300
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 21, 2023
Details:
VE202 is a first-in-class, orally administered, investigational live biotherapeutic product (LBP) consortium consisting of 16 strains of bacteria, which is investigated for the treatment of ulcerative colitis.
Lead Product(s): VE202,Vancomycin Hydrochloride
Therapeutic Area: Immunology Brand Name: VE202
Study Phase: Phase IIProduct Type: Probiotic
Sponsor: Vedanta Biosciences
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 10, 2023
Lead Product(s) : VE202,Vancomycin Hydrochloride
Therapeutic Area : Immunology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Vedanta Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VE202 is a first-in-class, orally administered, investigational live biotherapeutic product (LBP) consortium consisting of 16 strains of bacteria, which is investigated for the treatment of ulcerative colitis.
Product Name : VE202
Product Type : Probiotic
Upfront Cash : Inapplicable
April 10, 2023
Details:
LYT-300 (allopregnanolone) is a positive allosteric modulator of γ-aminobutyric-acid type A (GABAA) receptors and has been shown to regulate mood and other neurological conditions. It is be developed for anxiety and postpartum depression treatment.
Lead Product(s): Allopregnanolone
Therapeutic Area: Psychiatry/Psychology Brand Name: LYT-300
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 14, 2023
Lead Product(s) : Allopregnanolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LYT-300 (allopregnanolone) is a positive allosteric modulator of γ-aminobutyric-acid type A (GABAA) receptors and has been shown to regulate mood and other neurological conditions. It is be developed for anxiety and postpartum depression treatment.
Product Name : LYT-300
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 14, 2023
Details:
The funding will advance Phase 2 trial of company's therapeutic candidate, LYT-300, an oral prodrug of allopregnanolone, for the treatment of Fragile X-associated Tremor Ataxia Syndrome (FXTAS).
Lead Product(s): Allopregnanolone
Therapeutic Area: Neurology Brand Name: LYT-300
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: US Department of Defense
Deal Size: $11.4 million Upfront Cash: Undisclosed
Deal Type: Funding January 08, 2023
Lead Product(s) : Allopregnanolone
Therapeutic Area : Neurology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : US Department of Defense
Deal Size : $11.4 million
Deal Type : Funding
Details : The funding will advance Phase 2 trial of company's therapeutic candidate, LYT-300, an oral prodrug of allopregnanolone, for the treatment of Fragile X-associated Tremor Ataxia Syndrome (FXTAS).
Product Name : LYT-300
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 08, 2023
ABOUT THIS PAGE